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a  b  s  t  r  a  c  t
The  efﬁcacy  of  single  oral  treatment  of  sarolaner  (SimparicaTM, Zoetis),  a novel  isoxazoline  compound,
was  evaluated  against  four  tick  species  known  to  commonly  infest  dogs  in  Europe.  Eight  laboratory
studies  were  conducted  using  adult  purpose-bred  Beagle  dogs.  In  each  study,  16 animals  were  randomly
allocated  to  one  of  two  treatment  groups  based  on pre-treatment  host-suitability  tick  counts.  Dogs  were
infested  with  50 unfed  adult  Dermacentor  reticulatus  (two  studies),  Ixodes hexagonus  (three  studies),
Ixodes  ricinus  (two  studies)  or Rhipicephalus  sanguineus  (one  study)  ticks  on Days  −2, 5,  12,  19,  26 and
33.  On  Day  0,  dogs  were  treated  orally  with  placebo  or sarolaner  tablets  providing  the  minimum  dose  of
2.0 mg/kg  bodyweight  and  tick  counts  were  conducted  48 h after  treatment  and  after  each  subsequent
weekly  re-infestation.  There  were  no treatment-related  adverse  reactions  in any  of the  studies.  Dogs  in
the placebo-treated  group  maintained  tick  infestations  throughout  the  studies.  Geometric  mean  live tick
counts  were  signiﬁcantly  (P ≤  0.0001)  lower  in  the sarolaner-treated  group  compared  to  the  tick  counts
in the  placebo  group  at all  time-points.  A  single  oral  administration  of  sarolaner  resulted  in  100%  efﬁcacy
against  existing  infestations  of  all tick  species  except  R. sanguineus,  for  which  the  efﬁcacy  was  99.7%,
within  48  h.  Efﬁcacy  against  weekly  re-infestations  was  ≥97.5%  for all tick  species  for 35 days.Thus,  a single  dose  of  sarolaner  administered  orally  at the  minimum  dosage  of 2 mg/kg,  resulted  in
≥99.7%  efﬁcacy  within  48 h against  existing  tick  infestations,  and  in  ≥97.5%  efﬁcacy  against  weekly  re-
infestations,  for at  least 35 days  after  treatment.  These  studies  conﬁrmed  that  administration  of the
minimum  dose of  sarolaner  will  provide  treatment  of  existing  infestations  and  give  at least  one  month
of  control  against  re-infestation  by  the  common  tick  species  affecting  dogs  in Europe.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Ticks are one of the most common ectoparasites infesting dogs.
ick infestation can lead to nuisance, alopecia and skin irrita-
ion. Heavy infestations can even lead to anemia (Dryden and
ayne, 2004). Canine tick infestations are thus of direct veterinary
mportance to the animal, but are also important in the distri-
ution of tick-borne diseases (Needham and Teel, 1991; Beugnet
nd Marié, 2009). Ticks are responsible for the transmission of a
umber of disease agents, of which some are zoonotic and some
∗ Corresponding author.
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cause serious, even life-threatening conditions (Dryden and Payne,
2004). Zoonotic infections include Lyme disease caused by Bor-
relia burgdorferi, which is transmitted by Ixodes species (Beugnet
and Marié, 2009). Other tick-borne pathogens cause predominantly
dog-speciﬁc infections, such as Babesia canis, primarily transmit-
ted by Dermacentor spp., and Ehrlichia canis, primarily transmitted
by Rhipicephalus sanguineus (Chomel, 2011; Dantas-Torres et al.,
2012).
Tick prevention has historically been based on the monthly use
of acaricidal compounds applied as topical formulations (Dryden
and Payne, 2004; Rust, 2005) but recently two isoxazoline com-
pounds for use in dogs have been introduced in Europe that provide
treatment and prevention of ﬂea and tick infestations after oral
treatment (Robertson-Plouch et al., 2008; Rohdich et al., 2014;
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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hoop et al., 2014). Sarolaner (SimparicaTM, Zoetis) is a novel isox-
zoline with potent activity against ectoparasites (McTier et al.,
016). The objective of this series of studies was to evaluate the
fﬁcacy of sarolaner against four tick species of major importance
n Europe, each of which has potential to transmit disease organ-
sms (Beugnet and Marié, 2009). Eight laboratory studies were
onducted to evaluate the efﬁcacy of sarolaner against existing tick
nfestations and against re-infestations for a period of ﬁve weeks
fter treatment.
. Materials and methods
The eight laboratory studies were conducted to evaluate against
he following tick species commonly infesting dogs in Europe: Der-
acentor reticulatus (ornate dog tick; two studies), Ixodes hexagonus
hedgehog tick; three studies), Ixodes ricinus (castor bean tick; two
tudies), and R. sanguineus (brown dog tick; one study). All stud-
es were conducted in accordance with the World Association for
he Advancement of Veterinary Parasitology (WAAVP) guidelines
or evaluating the efﬁcacy of parasiticides for the treatment, pre-
ention and control of ﬂea and tick infestation on dogs and cats
Marchiondo et al. 2013) and complied with Good Clinical Prac-
ices (VICH guideline GL9, 2000). All studies were approved by the
oetis Ethical Review Committee and by the study site’s Ethical
eview Committee.
.1. Animals
All dogs used in these studies had not been treated with an
ctoparasiticide for at least 60 days, had demonstrated good tick
etention prior to treatment, and were in good health at enroll-
ent. Sixteen different purpose-bred Beagles, including both sexes,
ere enrolled in each study. Dogs ranged in age from 12 months
o 7 years, and weighed between 8.3 kg and 32.0 kg. Female dogs
ere conﬁrmed not to be pregnant or lactating. Each dog was  indi-
idually identiﬁed by a unique and permanent code (microchip
r tattoo). Dogs were housed in individual indoor pens such that
o physical contact was possible between them, and the possibil-
ty of tick transfer among animals was minimal. Dogs were fed an
ppropriate maintenance ration of a commercial canine diet for the
uration of the study. Water was available ad libitum.
.2. Study methods
Day 0 for each study was the day dogs were administered the
tudy treatment. Dogs were acclimated to the study conditions
or at least 7 days prior to treatment. For tick infestations, a pre-
ounted aliquot of approximately 50 adult unfed ticks were placed
nto the hair coat and allowed to disperse on the dog. Ticks were
pplied in an approximate 1:1 sex ratio, with the exception of one
. ricinus study in which a 3:2 female to male ratio was  used as this
as indicated per previous use for that tick strain.
Tick counts were performed by personnel trained in the stan-
ard procedures in use at the test facility. Personnel changed pro-
ective clothing between dogs to avoid any cross-contamination,
nd personnel conducting parasite or other observations were
naware of treatment assignments. Initially, the entire dog’s entire
ody was examined, pushing the hair against its natural nap, expos-
ng, counting and removing the ticks. After the manual inspection,
n extra-ﬁne tooth comb was used to comb the animal to remove
ny missed ticks. Each dog was examined for at least 10 min. If ticks
ere encountered in the last minute, combing was continued in
ne minute increments until no ticks were encountered. The ticks
ere examined to assess viability (movement and reaction to CO2
timulation) and the numbers of live ticks was quantiﬁed.sitology 222 (2016) 33–36
At least 16 animals arrived into the housing facilities on or before
Day −7. General health observations were performed at least once
a day from the start of the acclimation period. All dogs were given
a physical examination to evaluate general health and suitability
for inclusion into the study. The dogs were examined to ensure
they were free of ticks and were then infested to determine the
host suitability between Day −9 and Day −7. The live attached ticks
present on each dog were counted and removed at 48 (±2) hours
after infestation. The 16 dogs with the highest counts were selected
for inclusion, ranked by decreasing tick count into blocks of two
and randomly allocated within block to treatment with placebo
or sarolaner tablets. Blocks of dogs were randomly assigned to
adjacent pens within the test facility. Dogs were moved into their
allocated pens on or before Day −2.
Dogs were weighed and infested with ticks on Day −2. On Day 0,
the dogs were dosed orally with placebo (SimparicaTM formulation
without active ingredient sarolaner) or sarolaner strengths of 5, 10,
20, or 40 mg  such that the sarolaner dose was as close as possible
to 2 mg/kg without under-dosing.
Each dog was offered its regular food ration ∼20 min  before dos-
ing. Dogs were hand-pilled to ensure accurate dose delivery. Each
dog was observed for a minimum of 1 min  after dosing for evidence
that the dose was  swallowed, and for potential adverse events asso-
ciated with treatment and then for up to 2 h for any signs of emesis.
Dogs were observed for general health and any reaction to treat-
ment approximately 1, 3 and 6 h after treatment. On Day 2, each
dog was examined to remove and count ticks. In all studies except
two of the three conducted against I. hexagonus,  animals were sub-
sequently re-infested with ticks on Days 5, 12, 19, 26 and 33. In one
I. hexagonus study dogs were re-infested only on Days 19 and 26,
and in one study only on Day 33. Dogs were examined, combed and
parasites counted 48 (±2) hours after each infestation.
Ticks were sourced from multiple laboratory maintained
colonies with isolates all originating from Europe. These ticks were
originally isolated from the ﬁeld, and new ticks had been introduced
into each colony within the previous ten years.
2.3. Data analysis
The individual dog was  the experimental unit and the primary
endpoint was  live tick counts. Tick counts were transformed by the
loge(count + 1) transformation prior to analysis in order to stabilize
the variance and normalize the data. Using the PROC MIXED proce-
dure (SAS 8.2, Cary NC), transformed counts were analyzed using a
mixed linear model for repeated measures. The model included the
ﬁxed effect of treatment, day of study and the interaction between
treatment and day of study. The random effects included room,
block within room, the interaction between block and treatment
within room (animal term) and error. Testing was two-sided at
the signiﬁcance level  = 0.05. Percent efﬁcacy was calculated using
Abbott’s formula:
%reduction = 100 × meancount (placebo) − meancount (treated)
meancount (placebo)
3. Results
3.1. Efﬁcacy
Dogs in the placebo-treated group maintained tick infestations
throughout the studies (Tables 1–4 ).
For D. reticulatus,  efﬁcacy against existing infestations was  100%
at 48 h after treatment in both studies. Against subsequent weekly
re-infestations, efﬁcacy 48 h after infestation was  ≥99.0% in one
study and 100% in the second study through 35 days post treat-
ment (Table 1). Efﬁcacy against existing infestations of I. hexagonus
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Table  1
Geometric (arithmetic) mean live Dermacentor reticulatus (ornate dog tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in two  laboratory studies.
Tick Strain Origin Placebo Sarolaner
Day Mean Range Mean Range % Efﬁcacy
Europe (various countries) 2 23.4 (26.5) 9– 44 0.0* (0.0) 0–0 100
7  19.1 (20.5) 10–34 0.0* (0.0) 0–0 100
14  11.1 (12.1) 4–20 0.0* (0.0) 0–0 100
21  24.5 (25.1) 14–31 0.0* (0.0) 0–0 100
28  16.4 (18.0) 6–37 0.0* (0.0) 0–0 100
35  16.7 (18.8) 6–38 0.0* (0.0) 0–0 100
Ireland/The Netherlands 2 19.5 (21.3) 10–35 0.0* (0.0) 0–0 100
7  20.9 (23.3) 8–41 0.0* (0.0) 0–0 100
14  19.4 (20.4) 13–34 0.2* (0.4) 0–3 99.0 (98.2)
21  18.7 (20.8) 10–37 0.0* (0.0) 0–0 100
28  18.0 (18.9) 12–31 0.1* (0.1) 0–1 99.5 (99.3)
35  19.7 (21.3) 7–32 0.1* (0.1) 0–1 99.5 (99.4)
Table 2
Geometric (arithmetic) mean live Ixodes hexagonus (hedgehog tick) counts and ranges for placebo control and treated dogs and efﬁcacy relative to controls for dogs treated
once  orally with sarolaner chewable tablets at 2 mg/kg in two laboratory studies.
Tick Strain Origin Placebo Sarolaner
Day Mean Range Mean Range % Efﬁcacy
UK 2 13.2 (14.3) 7–23 0.0* (0.0) 0– 0 100
21  11.4 (13.0) 3–23 0.0* (0.0) 0–0 100
28  12.9 (13.8) 6– 20 0.1* (0.1) 0–1 99.3 (99.1)
UK  2 11.5 (11.9) 7– 15 0.0* (0.0) 0–0 100
35  8.9 (9.1) 6– 12 0.0* (0.0) 0–0 100
The  Netherlands 2 13.5 (14.1) 7–23 0.0* (0.0) 0–0 100
7  16.5 (17.1) 11–26 0.0* (0.0) 0–0 100
14  17.1 (17.8) 11–26 0.0* (0.0) 0–0 100
21  13.7 (14.5) 8–26 0.0* (0.0) 0–0 100
28  10.5 (14.3) 0–25 0.0* (0.0) 0–0 100
35  12.2 (14.1) 4– 22 0.0* (0.0) 0– 0 100
Table 3
Geometric (arithmetic) mean live Ixodes ricinus (castor bean tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to control for dogs
treated once orally with sarolaner chewable tablets at 2 mg/kg in two  laboratory studies.
Tick Strain Origin Placebo Sarolaner
Day Mean Range Mean Range % Efﬁcacy
Germany/Slovakia 2 23.1 (23.6) 15–31 0.0* (0.0) 0–0 100
7  23.6 (24.0) 16–29 0.0* (0.0) 0–0 100
14  20.1 (20.3) 17–25 0.0* (0.0) 0–0 100
21  16.6 (17.6) 8–24 0.0* (0.0) 0–0 100
28  12.6 (13.6) 7–23 0.2* (0.4) 0–3 98.5 (97.2)
35  15.4 (15.8) 9–21 0.0* (0.0) 0–0 100
Germany 2 17.3 (17.4) 14–20 0.0* (0.0) 0–0 100
7  16.8 (16.9) 13–19 0.0* (0.0) 0–0 100
14  15.5 (15.6) 11–19 0.0* (0.0) 0–0 100
21  16.2 (16.5) 12–20 0.1* (0.1) 0–1 99.4 (99.2)
28  16.0 (16.1) 12–19 0.2* (0.3) 0–1 98.8 (98.4)
35  16.2 (16.4) 14–22 0.4* (0.8) 0–4 97.5 (95.4)
Table 4
Geometric (arithmetic) mean live Rhipicephalus sanguineus (brown dog tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls
for  dogs treated once orally with sarolaner chewable tablets at 2 mg/kg in a laboratory study.
Tick Strain Origin Placebo Sarolaner
Day Mean Range Mean Range % Efﬁcacy
Germany 2 28.0 (29.4) 12–39 0.1* (0.1) 0–1 99.7 (99.6)
7  25.9 (27.0) 17–40 0.0* (0.0) 0–0 100
14  23.4 (24.1) 16–34 0.0* (0.0) 0–0 100
21  24.6 (25.5) 15–37 0.1* (0.1) 0–1 99.6 (99.5)
28  18.6 (19.9) 12–39 0.1* (0.1) 0–1 99.5 (99.4)
35  24.1 (25.0) 16–33 0.1* (0.1) 0–1 99.6 (99.5)
3 y Para
w
a
p
w
i
q
i
E
4
i
s
s
t
3
o
4
c
t
a
p
d
d
b
a
a
a
d
d
w
2
s
t
l
m
e
a
o
s
d
a
a
i
C
s
e
u
a
o
c
t
h
a
5
(
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as 100% at 48 h after treatment in all three studies. Efﬁcacy 48 h
fter subsequent weekly re-infestations was 100% through 35 days
ost-treatment, except on Day 28 in one study when the efﬁcacy
as 99.3% (Table 2). For I. ricinus, efﬁcacy was 100% against existing
nfestations at 48 h after treatment in both studies. After subse-
uent weekly re-infestations, efﬁcacy was ≥97.5% at 48 h after
nfestation through 35 days post treatment in both studies (Table 3).
fﬁcacy against existing infestations of R. sanguineus was  99.7% at
8 h after treatment and ≥99.5% at 48 h after subsequent weekly re-
nfestations through 35 days post treatment (Table 4). For all tick
pecies, the mean live tick counts for sarolaner-treated dogs were
igniﬁcantly lower than those for placebo-treated dogs at all post
reatment counts (P ≤ 0.0001).
.2. Health observations
No adverse events related to treatment with sarolaner were
bserved in any study.
. Discussion
The recent development of oral formulations of the isoxazoline
lass compounds for the treatment and prevention of tick infes-
ations provides animal owners with an alternative to topically
pplied treatments, which can be messy to apply. Oral treatments
rovide dosing convenience, and for the dog to be handled imme-
iately after treatment without the risk of being exposed to the
rug. Furthermore, orally administered products are not affected
y external factors such as bathing, rain or skin disease that might
ffect the uptake or efﬁcacy of topically applied products, which is
n added beneﬁt for sporting dogs and those with outdoor lifestyles
nd that may  be more at risk of exposure to ticks that can carry
isease.
Sarolaner is a new member of the isoxazoline class that was
eveloped to provide efﬁcacy against existing tick infestations as
ell as persistent acaricidal efﬁcacy for one month (McTier et al.,
016). Thus, it was expected that a single oral treatment with
arolaner at a minimum dosage of 2 mg/kg would provide consis-
ent efﬁcacy against the main ticks infesting dogs in the EU for at
east one month.
In the eight laboratory studies presented here, a single oral treat-
ent with the chewable formulation of sarolaner provided a 100%
fﬁcacy against existing infestations of D. reticulatus, I. hexagonus,
nd I. ricinus,  and 99.7% efﬁcacy against R. sanguineus within 48 h
f dosing. Following weekly re-infestations of all four species, the
ingle treatment resulted in > 99% reductions in live ticks for 35
ays.
Sarolaner is the only isoxazoline with demonstrated efﬁcacy
gainst I. hexagonus.  Although less prevalent compared to I. ricinus
nd less frequently evaluated, the hedgehog tick has been reported
n 8.8–22.6% of examined dogs in recent studies (Smith et al., 2011;
laerebout et al., 2013; Beck et al., 2014). Furthermore, I. hexagonus
eems to be as frequently infected with common tick-borne dis-
ases as I. ricinus (Schreiber et al., 2014; Claerebout et al., 2013),
nderlining the importance of having a high and persistent efﬁcacy
gainst this tick species. The importance of efﬁcacy until the end
f the claimed treatment interval is not only driven by the direct
linical effects of tick infestations, but is also important in light of
he risk of transmission of tick-borne diseases. The current studies
ave demonstrated that sarolaner provides a consistent efﬁcacy for
t least ﬁve weeks against the four major European tick species.. Conclusions
The consistent efﬁcacy of a single oral treatment of sarolaner
SimparicaTM), at the proposed minimum dose of 2.0 mg/kg, againstsitology 222 (2016) 33–36
the four major EU tick species was demonstrated against existing
infestations and weekly re-infestations for at least 5 weeks. Efﬁ-
cacy of ≥ 99.7% was  achieved versus existing infestations within
48 h after treatment. Efﬁcacy was  maintained at greater than 97.5%
within 48 h after infestation for the 35 day duration of all studies.
Conﬂict of interest
The studies reported here were funded by Zoetis. TG, CB, SPM,
NS, AL and RHS are employees of Zoetis. SG, CS, PD, VD, JL, and
AM are independent investigators contracted for these studies.
All authors assisted with the design and conduct of the studies,
interpretation of the data and manuscript review. There were no
conﬂicting interests that could have inﬂuenced the conduct and
reporting of these studies.
Acknowledgements
The authors would like to thank Anne McLoughlin and Veronica
Doyle for their assistance in running the studies at Charles Rivers
Laboratories. The authors would like to thank Douglas Rugg for the
assistance in preparing the manuscript.
References
Beck, S., Schreiber, C., Schein, E., Krücken, J., Baldermann, C., Pachnicke, S., von
Samson-Himmelstjerna, G., Kohn, B., 2014. Tick infestation and prophylaxis of
dogs in northeastern Germany: a prospective study. Ticks Tick Borne Dis. 5,
336–342.
Beugnet, F., Marié, J.L., 2009. Emerging arthropod-borne diseases of companion
animals in Europe. Vet. Parasitol. 163 (4), 298–305.
Chomel, B., 2011. Tick-borne infections in dogs-an emerging infectious threat. Vet.
Parasitol. 179, 294–301.
Claerebout, E., Losson, B., Cochez, C., Casaert, S., Dalemans, A.C., De Cat, A., Madder,
M., Saegerman, C., Heyman, P., Lempereur, L., 2013. Ticks and associated
pathogens collected from dogs and cats in Belgium. Parasites Vectors 6, 183.
Dantas-Torres, F., Capelli, G., Giannelli, A., Ramos, R.A., Lia, R.P., Cantacessi, C., de
Caprariis, D., De Tommasi, A.S., Latrofa, M.S., Lacasella, V., Tarallo, V.D., Di
Paola, G., Qurollo, B., Breitschwerdt, E., Stanneck, D., Otranto, D., 2012. Efﬁcacy
of  an imidacloprid/ﬂumethrin collar against ﬂeas, ticks and tick-borne
pathogens in dogs. Parasites Vectors 6, 245.
Dryden, M.W.,  Payne, P.A., 2004. Biology and control of ticks infesting dogs and
cats in North America. Vet. Ther. 26, 2–16.
Marchiondo, A.A., Holdsworth, P.A., Fourie, L.J., Rugg, D., Hellmann, K., Snyder, D.E.,
Dryden, M.W.,  2013. World Association for the Advancement of Veterinary
Parasitology (W.A.A.V.P.) second edition: guidelines for evaluating the efﬁcacy
of parasiticides for the treatment, prevention and control of ﬂea and tick
infestations on dogs and cats. Vet. Parasitol. 194, 84–97.
McTier, T.L., Six, R., Becskei, C., Fourie, J.J., Pullins, A., Hedges, L., Mahabir, S., Myers,
M.R., Slootmans, N., 2016. Determination of the effective dose of a novel oral
formulation of sarolaner (SimparicaTM) for the treatment and month-long
control of ﬂeas and ticks on dogs. Vet. Parasitol. (Feburary (17)), http://dx.doi.
org/10.1016/j.vetpar.2016.02.016 (This Edition) pii: S0304-4017(16)30038-3.
Needham, G.R., Teel, P.D., 1991. Off-host physiological ecology of ticks. Annu. Rev.
Entomol. 36, 659–681.
Robertson-Plouch, C., Baker, K.A., Hozak, R.R., Zimmermann, A.G., Parks, S.C., Herr,
C.,  Hart, L.M., Jay, J., Hutchens, D.E., Snyder, D.E., 2008. Clinical ﬁeld study of the
safety and efﬁcacy of spinosad chewable tablets for controlling ﬂeas on dogs.
Vet.  Ther. 9, 26–36.
Rohdich, N., Roepke, R.K.A., Zschiesche, E., 2014. A randomized, blinded, controlled
and multi-centered ﬁeld study comparing the efﬁcacy and safety of BravectoTM
(ﬂuralaner) against FrontlineTM (ﬁpronil) in ﬂea- and tick-infested dogs.
Parasites Vectors 7, 83.
Rust, M.K., 2005. Advances in the control of Ctenocephalides felis (cat ﬂea) on cats
and dogs. Trends Parasitol. 21, 232–236.
Schreiber, C., Krücken, J., Beck, S., Maaz, D., Pachnicke, S., Krieger, K., Gross, M.,
Kohn, B., von Samson-Himmelstjerna, G., 2014. Pathogens in ticks collected
from dogs in Berlin/Brandenburg, Germany. Parasites Vectors 7, 535.
Shoop, W.L., Hartline, E.J., Gould, B.R., Waddell, M.E., McDowell, R.G., Kinney, J.B.,
Lahm, G.P., Long, J.K., Xu, M.,  Wagerle, T., Jones, G.S., Dietrich, R.F., Cordova, D.,
Schroeder, M.E., Rhoades, D.F., Benner, E.A., Confalone, P.N., 2014. DiscoverySmith, F.D., Ballantyne, R., Morgan, E.R., Wall, R., 2011. Prevalence, distribution and
risk associated with tick infestation of dogs in Great Britain. Med. Vet. Entomol.
25, 377–384.
